EMT Transition States during Tumor Progression and Metastasis.

Epithelial-mesenchymal transition (EMT) is a process in which epithelial cells acquire mesenchymal features. In cancer, EMT is associated with tumor initiation, invasion, metastasis, and resistance to therapy. Recently, it has been demonstrated that EMT is not a binary process, but occurs through distinct cellular states. Here, we review the recent studies that demonstrate the existence of these different EMT states in cancer and the mechanisms regulating their functions. We discuss the different functional characteristics, such as proliferation, propagation, plasticity, invasion, and metastasis associated with the distinct EMT states. We summarize the role of the transcriptional and epigenetic landscapes, gene regulatory network and their surrounding niche in controlling the transition through the different EMT states.

[1]  J. Cerhan,et al.  Association between keratin and vimentin expression, malignant phenotype, and survival in postmenopausal breast cancer patients. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[2]  Sridhar Ramaswamy,et al.  Circulating Breast Tumor Cells Exhibit Dynamic Changes in Epithelial and Mesenchymal Composition , 2013, Science.

[3]  A. Puisieux,et al.  Generation of Breast Cancer Stem Cells through Epithelial-Mesenchymal Transition , 2008, PloS one.

[4]  T. Voet,et al.  Identification of the tumour transition states occurring during EMT , 2018, Nature.

[5]  E. Furth,et al.  EMT Subtype Influences Epithelial Plasticity and Mode of Cell Migration. , 2018, Developmental cell.

[6]  N. Loman,et al.  Longitudinal enumeration and cluster evaluation of circulating tumor cells improve prognostication for patients with newly diagnosed metastatic breast cancer in a prospective observational trial , 2018, Breast Cancer Research.

[7]  T. Keck,et al.  Cancer cell invasion and EMT marker expression: a three‐dimensional study of the human cancer–host interface , 2014, The Journal of pathology.

[8]  H. Levine,et al.  Hybrid epithelial/mesenchymal phenotype(s): The 'fittest' for metastasis? , 2018, Biochimica et biophysica acta. Reviews on cancer.

[9]  C. Blanpain,et al.  Cancer Stem Cells: Basic Concepts and Therapeutic Implications. , 2016, Annual review of pathology.

[10]  Maximilian Reichert,et al.  EMT and Dissemination Precede Pancreatic Tumor Formation , 2012, Cell.

[11]  D. Beer,et al.  Poor Prognosis Indicated by Venous Circulating Tumor Cell Clusters in Early-Stage Lung Cancers. , 2017, Cancer research.

[12]  C. Nelson,et al.  A Collective Route to Head and Neck Cancer Metastasis , 2018, Scientific Reports.

[13]  H. Popper,et al.  Bulk tumour cell migration in lung carcinomas might be more common than epithelial-mesenchymal transition and be differently regulated , 2018, BMC Cancer.

[14]  A. G. de Herreros,et al.  Wilms' Tumor Protein Induces an Epithelial-Mesenchymal Hybrid Differentiation State in Clear Cell Renal Cell Carcinoma , 2014, PloS one.

[15]  R. Weinberg,et al.  Upholding a role for EMT in breast cancer metastasis , 2017, Nature.

[16]  Erik Sahai,et al.  Mesenchymal Cancer Cell-Stroma Crosstalk Promotes Niche Activation, Epithelial Reversion, and Metastatic Colonization , 2015, Cell reports.

[17]  T. Möller,et al.  Epithelial phenotype confers resistance of ovarian cancer cells to oncolytic adenoviruses. , 2009, Cancer research.

[18]  D. Planchard,et al.  Detection of circulating tumour cells with a hybrid (epithelial/mesenchymal) phenotype in patients with metastatic non-small cell lung cancer , 2011, British Journal of Cancer.

[19]  M. Miyazaki,et al.  Prrx1 isoform switching regulates pancreatic cancer invasion and metastatic colonization , 2016, Genes & development.

[20]  Jason T. George,et al.  A mechanism-based computational model to capture the interconnections among epithelial-mesenchymal transition, cancer stem cells and Notch-Jagged signaling , 2018, bioRxiv.

[21]  W. Choi,et al.  Epithelial-to-mesenchymal transition leads to loss of EpCAM and different physical properties in circulating tumor cells from metastatic breast cancer , 2016, Oncotarget.

[22]  Xin-hua Liang,et al.  Cytokeratin-14 contributes to collective invasion of salivary adenoid cystic carcinoma , 2017, PloS one.

[23]  Eshel Ben-Jacob,et al.  Coupling the modules of EMT and stemness: A tunable ‘stemness window’ model , 2015, Oncotarget.

[24]  Stephen T. C. Wong,et al.  In Vivo Visualization and Characterization of Epithelial-Mesenchymal Transition in Breast Tumors. , 2016, Cancer research.

[25]  Hushan Yang,et al.  Longitudinally collected CTCs and CTC-clusters and clinical outcomes of metastatic breast cancer , 2016, Breast Cancer Research and Treatment.

[26]  Michael B. Stadler,et al.  PIK3CAH1047R induces multipotency and multi-lineage mammary tumours , 2015, Nature.

[27]  N. Colburn,et al.  Transgenic mice demonstrate AP-1 (activator protein-1) transactivation is required for tumor promotion. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[28]  J. Onuchic,et al.  Numb prevents a complete epithelial–mesenchymal transition by modulating Notch signalling , 2017, Journal of The Royal Society Interface.

[29]  H. Levine,et al.  Clinical Medicine , 1997 .

[30]  C. Pilarsky,et al.  The EMT-activator Zeb1 is a key factor for cell plasticity and promotes metastasis in pancreatic cancer , 2017, Nature Cell Biology.

[31]  Joseph Rosenbluh,et al.  KRAS and YAP1 Converge to Regulate EMT and Tumor Survival , 2014, Cell.

[32]  N. Jordan,et al.  Tracking the intermediate stages of epithelial-mesenchymal transition in epithelial stem cells and cancer , 2011, Cell cycle.

[33]  M. Noguchi,et al.  Clinical significance of E-cadherin and vimentin co-expression in breast cancer. , 1996, International journal of oncology.

[34]  S. Sen,et al.  CSF-1/CSF-1R axis is associated with epithelial/mesenchymal hybrid phenotype in epithelial-like inflammatory breast cancer , 2018, Scientific Reports.

[35]  Hushan Yang,et al.  Prospective assessment of the prognostic value of circulating tumor cells and their clusters in patients with advanced-stage breast cancer , 2015, Breast Cancer Research and Treatment.

[36]  R. Paus,et al.  Runx1 Directly Promotes Proliferation of Hair Follicle Stem Cells and Epithelial Tumor Formation in Mouse Skin , 2010, Molecular and Cellular Biology.

[37]  R. Plummer,et al.  Detection of circulating tumour cell clusters in human glioblastoma , 2018, British Journal of Cancer.

[38]  Sridhar Ramaswamy,et al.  Circulating Tumor Cell Clusters Are Oligoclonal Precursors of Breast Cancer Metastasis , 2014, Cell.

[39]  Andrew J Armstrong,et al.  Angiogenesis , Metastasis , and the Cellular Microenvironment Circulating Tumor Cells from Patients with Advanced Prostate and Breast Cancer Display Both Epithelial and Mesenchymal Markers , 2011 .

[40]  Y. Sugisaki,et al.  Pulmonary carcinosarcoma: Immunohistochemical and ultrastructural studies , 1999, Pathology international.

[41]  A. Tajima,et al.  Next-generation sequencing analysis identifies genomic alterations in pathological morphologies: A case of pulmonary carcinosarcoma harboring EGFR mutations. , 2018, Lung cancer.

[42]  S. Ramaswamy,et al.  Twist, a Master Regulator of Morphogenesis, Plays an Essential Role in Tumor Metastasis , 2004, Cell.

[43]  Jeffrey D. Varner,et al.  Population Heterogeneity in the Epithelial to Mesenchymal Transition Is Controlled by NFAT and Phosphorylated Sp1 , 2015, bioRxiv.

[44]  R. Weinberg,et al.  Upholding a role for EMT in pancreatic cancer metastasis , 2017, Nature.

[45]  Mohit Kumar Jolly,et al.  Survival Outcomes in Cancer Patients Predicted by a Partial EMT Gene Expression Scoring Metric. , 2017, Cancer research.

[46]  Bogi Andersen,et al.  Mammary morphogenesis and regeneration require the inhibition of EMT at terminal end buds by Ovol2 transcriptional repressor. , 2014, Developmental cell.

[47]  M Choolani,et al.  An EMT spectrum defines an anoikis-resistant and spheroidogenic intermediate mesenchymal state that is sensitive to e-cadherin restoration by a src-kinase inhibitor, saracatinib (AZD0530) , 2013, Cell Death and Disease.

[48]  M. Vaidya,et al.  Vimentin regulates differentiation switch via modulation of keratin 14 levels and their expression together correlates with poor prognosis in oral cancer patients , 2017, PloS one.

[49]  G. Charras,et al.  In vivo collective cell migration requires an LPAR2-dependent increase in tissue fluidity , 2014, The Journal of cell biology.

[50]  E. Tokunaga,et al.  Epithelial Paradox: Clinical Significance of Coexpression of E‐cadherin and Vimentin With Regard to Invasion and Metastasis of Breast Cancer , 2018, Clinical breast cancer.

[51]  D. Gilmour,et al.  EMT 2.0: shaping epithelia through collective migration. , 2009, Current opinion in genetics & development.

[52]  Gema Moreno-Bueno,et al.  Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. , 2008, Cancer research.

[53]  Wenjun Guo,et al.  The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells , 2008, Cell.

[54]  K. Sundfeldt,et al.  TGF-β isoforms induce EMT independent migration of ovarian cancer cells , 2014, Cancer Cell International.

[55]  Jing Yang,et al.  Spatiotemporal regulation of epithelial-mesenchymal transition is essential for squamous cell carcinoma metastasis. , 2012, Cancer cell.

[56]  Eshel Ben-Jacob,et al.  Implications of the Hybrid Epithelial/Mesenchymal Phenotype in Metastasis , 2015, Front. Oncol..

[57]  R. Cason,et al.  Cutaneous carcinosarcoma and the EMT: to transition, or not to transition? That is the question , 2015, Virchows Archiv.

[58]  Cecilia Clementi,et al.  Jagged–Delta asymmetry in Notch signaling can give rise to a Sender/Receiver hybrid phenotype , 2015, Proceedings of the National Academy of Sciences.

[59]  T. Brabletz To differentiate or not — routes towards metastasis , 2012, Nature Reviews Cancer.

[60]  Caroline Dive,et al.  Circulating tumor cells as a window on metastasis biology in lung cancer. , 2011, The American journal of pathology.

[61]  Shawn M. Gillespie,et al.  Single-Cell Transcriptomic Analysis of Primary and Metastatic Tumor Ecosystems in Head and Neck Cancer , 2017, Cell.

[62]  L. Ellis,et al.  Epithelial–Mesenchymal Transitioned Circulating Tumor Cells Capture for Detecting Tumor Progression , 2014, Clinical Cancer Research.

[63]  Antonio Rosato,et al.  Genome-wide association between YAP/TAZ/TEAD and AP-1 at enhancers drives oncogenic growth , 2015, Nature Cell Biology.

[64]  Zhan-jun Chen,et al.  Circulating Tumor Cell Phenotype Indicates Poor Survival and Recurrence After Surgery for Hepatocellular Carcinoma , 2018, Digestive Diseases and Sciences.

[65]  Eshel Ben-Jacob,et al.  OVOL guides the epithelial-hybrid-mesenchymal transition , 2015, Oncotarget.

[66]  D. Zheng,et al.  ETS family transcriptional regulators drive chromatin dynamics and malignancy in squamous cell carcinomas , 2015, eLife.

[67]  M. Hendrix,et al.  Experimental co-expression of vimentin and keratin intermediate filaments in human breast cancer cells results in phenotypic interconversion and increased invasive behavior. , 1997, The American journal of pathology.

[68]  P. Bertolazzi,et al.  Characterization of epithelial-mesenchymal transition intermediate/hybrid phenotypes associated to resistance to EGFR inhibitors in non-small cell lung cancer cell lines , 2017, Oncotarget.

[69]  Dong Wang,et al.  Breast Cancer Stem Cells Transition between Epithelial and Mesenchymal States Reflective of their Normal Counterparts , 2013, Stem cell reports.

[70]  G. Berx,et al.  Regulatory networks defining EMT during cancer initiation and progression , 2013, Nature Reviews Cancer.

[71]  R. Weinberg,et al.  Distinct EMT programs control normal mammary stem cells and tumour-initiating cells , 2015, Nature.

[72]  A. Puisieux,et al.  Oncogenic roles of EMT-inducing transcription factors , 2014, Nature Cell Biology.

[73]  S. Fischer,et al.  Critical role of IkappaB kinase alpha in embryonic skin development and skin carcinogenesis. , 2009, Histology and histopathology.

[74]  E. Wagner,et al.  AP-1: a double-edged sword in tumorigenesis , 2003, Nature Reviews Cancer.

[75]  Richard O Hynes,et al.  Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. , 2011, Cancer cell.

[76]  Xudong Dai,et al.  Molecular portraits of epithelial, mesenchymal, and hybrid States in lung adenocarcinoma and their relevance to survival. , 2015, Cancer research.

[77]  D. Mavroudis,et al.  Variable expression levels of keratin and vimentin reveal differential EMT status of circulating tumor cells and correlation with clinical characteristics and outcome of patients with metastatic breast cancer , 2015, BMC Cancer.

[78]  King-Jen Chang,et al.  Rab11 collaborates E‐cadherin to promote collective cell migration and indicates a poor prognosis in colorectal carcinoma , 2016, European journal of clinical investigation.

[79]  C. Perou,et al.  Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma , 2006, Modern Pathology.

[80]  M. Nieto,et al.  Metastatic colonization requires the repression of the epithelial-mesenchymal transition inducer Prrx1. , 2012, Cancer cell.

[81]  J. Bartek,et al.  Correction: Analysis of Epithelial and Mesenchymal Markers in Ovarian Cancer Reveals Phenotypic Heterogeneity and Plasticity , 2011, PLoS ONE.

[82]  G. V. van Leenders,et al.  Morphological and immunohistochemical identification of epithelial-to-mesenchymal transition in clinical prostate cancer , 2015, Oncotarget.

[83]  Tian Hong,et al.  An Ovol2-Zeb1 Mutual Inhibitory Circuit Governs Bidirectional and Multi-step Transition between Epithelial and Mesenchymal States , 2015, PLoS Comput. Biol..

[84]  R. Kurman,et al.  The Significance of Epithelial Differences in Mixed Mesodermal Tumors of the Uterus: A Clinicopathologic and Immunohistochemical Study , 1990, The American journal of surgical pathology.

[85]  Andrew J. Ewald,et al.  Collective Invasion in Breast Cancer Requires a Conserved Basal Epithelial Program , 2013, Cell.

[86]  Jean Paul Thiery,et al.  EMT: 2016 , 2016, Cell.

[87]  A. del Sol,et al.  Stemness of the hybrid Epithelial/Mesenchymal State in Breast Cancer and Its Association with Poor Survival , 2015, PloS one.

[88]  E. Ben-Jacob,et al.  Stability of the hybrid epithelial/mesenchymal phenotype , 2016, Oncotarget.

[89]  Jingyu Zhang,et al.  TGF-β–induced epithelial-to-mesenchymal transition proceeds through stepwise activation of multiple feedback loops , 2014, Science Signaling.

[90]  P. Friedl,et al.  Collective cell migration in morphogenesis, regeneration and cancer , 2009, Nature Reviews Molecular Cell Biology.

[91]  Eshel Ben-Jacob,et al.  Modeling the Transitions between Collective and Solitary Migration Phenotypes in Cancer Metastasis , 2015, Scientific Reports.

[92]  J. Casanova,et al.  A common framework for EMT and collective cell migration , 2016, Development.

[93]  R. Gomis,et al.  Epithelial-mesenchymal transition can suppress major attributes of human epithelial tumor-initiating cells. , 2012, The Journal of clinical investigation.

[94]  Inna Kuperstein,et al.  Concomitant Notch activation and p53 deletion trigger epithelial-to-mesenchymal transition and metastasis in mouse gut , 2014, Nature Communications.

[95]  V. LeBleu,et al.  EMT Program is Dispensable for Metastasis but Induces Chemoresistance in Pancreatic Cancer , 2015, Nature.

[96]  R. Yi,et al.  Cell-Type-Specific Chromatin States Differentially Prime Squamous Cell Carcinoma Tumor-Initiating Cells for Epithelial to Mesenchymal Transition. , 2017, Cell stem cell.

[97]  M. Garcia-Blanco,et al.  Carcinosarcomas: tumors in transition? , 2015, Histology and histopathology.

[98]  T. Tan,et al.  Molecular characterization of breast cancer CTCs associated with brain metastasis , 2017, Nature Communications.

[99]  S. Rorive,et al.  YAP and TAZ are essential for basal and squamous cell carcinoma initiation , 2018, EMBO reports.

[100]  Stephen T. C. Wong,et al.  EMT is not required for lung metastasis but contributes to chemoresistance , 2016 .

[101]  Hong Wu,et al.  Tracking and Functional Characterization of Epithelial-Mesenchymal Transition and Mesenchymal Tumor Cells during Prostate Cancer Metastasis. , 2015, Cancer research.

[102]  T. Kamarul,et al.  Incomplete cellular reprogramming of colorectal cancer cells elicits an epithelial/mesenchymal hybrid phenotype , 2018, Journal of Biomedical Science.

[103]  I. Mackenzie,et al.  Cancer stem cells in squamous cell carcinoma switch between two distinct phenotypes that are preferentially migratory or proliferative. , 2011, Cancer research.

[104]  P. Bendahl,et al.  Prognostic impact of circulating tumor cell apoptosis and clusters in serial blood samples from patients with metastatic breast cancer in a prospective observational cohort , 2016, BMC Cancer.

[105]  J. Keene,et al.  Ras Post-transcriptionally Enhances a Pre-malignantly Primed EMT to Promote Invasion , 2018, iScience.

[106]  Albert C. Chen,et al.  Matrix stiffness drives Epithelial-Mesenchymal Transition and tumour metastasis through a TWIST1-G3BP2 mechanotransduction pathway , 2015, Nature Cell Biology.

[107]  R. Cason,et al.  Cutaneous carcinosarcoma: further insights into its mutational landscape through massive parallel genome sequencing , 2014, Virchows Archiv.

[108]  May Yin Lee,et al.  Reactivation of multipotency by oncogenic PIK3CA induces breast tumour heterogeneity , 2015, Nature.

[109]  N. Yang,et al.  Classification of Circulating Tumor Cells by Epithelial-Mesenchymal Transition Markers , 2015, PloS one.

[110]  Jill M. Westcott,et al.  ΔNp63α Promotes Breast Cancer Cell Motility through the Selective Activation of Components of the Epithelial-to-Mesenchymal Transition Program. , 2015, Cancer research.

[112]  W. Woodward,et al.  Inflammatory breast cancer: a model for investigating cluster-based dissemination , 2017, npj Breast Cancer.

[113]  R. Zeillinger,et al.  Small cell lung cancer: model of circulating tumor cell tumorospheres in chemoresistance , 2017, Scientific Reports.

[114]  D. Grignon,et al.  Sarcomatoid renal cell carcinoma. An immunohistochemical study of 18 cases. , 1993, Archives of pathology & laboratory medicine.